HIV-CRISP: A same-day test-and-switch tool for HIV viral load and drug resistance
Official title: HIV-CRISP for Same Visit Test and Switch Viral Load and Resistance Testing
Funded at Case Western Reserve University · NIH-11411739 · Data updated 2026-11-12
A new at-your-side test uses CRISPR and a microfluidic chip to quickly measure HIV amount and resistance to common drugs during the same clinic visit.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | May 21, 2026 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $816,379 |
| NIH project number | 1R01AI192084-01A1 |
| Project ID | NIH-11411739 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults living with HIV who need resistance testing to guide ART changes, including patients in rural or resource-limited settings.
✕Less likely to help
Patients who already have rapid, same-visit resistance testing or those not currently considering changing ART may see limited direct benefit.
What this research studies
This project aims to bring a fast, affordable point-of-care test to people with HIV so clinicians can decide on a new treatment right away. It combines a CRISPR-based detection method with a bioinspired microfluidic chip to measure viral load and resistance to four major ART classes in one test. The goal is to reduce the need for expensive lab work, shorten wait times, and improve treatment durability, especially in rural or under-resourced clinics. By enabling same-visit decisions, this work could help more people stayVirally suppressed and minimize regimen changes due to resistance.
Why it matters
Potential benefit: If successful, patients could get faster, more accurate treatment changes at their first visit, improving viral suppression rates.
How similar studies have gone: Previous resistance testing relies on centralized labs; the CRISPR-based, point-of-care approach is promising but requires further validation in real-world settings.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Draz, Mohamed — Case Western Reserve University
- Study coordinator: Draz, Mohamed
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.